Nrg2-KO Mouse
一般名
Nrg2-KO
製品ID
S-KO-17204
背景情報
C57BL/6JCya
系統ID
KOCMP-100042150-Nrg2-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Nrg2-KO Mouse（カタログ番号S-KO-17204）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Nrg2-KO
系統ID
KOCMP-100042150-Nrg2-B6J-VA
遺伝子名
製品ID
S-KO-17204
遺伝子別名
Don1, NTAK
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 18
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000115713
NCBIトランスクリプトID
NM_001167891
ターゲット領域
Exon 2~9
有効領域の大きさ
~32.8 kb
遺伝子研究の概要
Nrg2, a member of the neuregulin family, belongs to the EGF family of growth factors. It contains a receptor-binding EGF-like domain and mediates binding to cellular receptors, with its functions potentially related to multiple cellular processes [1,7].
In cancer, NRG2 fusions have been identified in solid tumors and may contribute to oncogenesis through ligand-fusion mechanisms, potentially enhancing ectopic expression of the NRG/ErbB receptor-ligand and triggering downstream pathways [1,4,6].
In prostate regeneration, mesenchymal cells can express Nrg2 in an androgen-driven manner, acting in a paracrine fashion on luminal cells to contribute to prostate regeneration [2].
In gliomas, NRG2 is expressed to varying extents and can promote the migration of glioma cells in vitro, suggesting that targeting NRG2 signaling may reverse glioma cell metastasis [3].
In breast cancer, NRG2 acts as a tumor suppressor, and its low expression is related to poor survival rate, with its depletion promoting cancer cell proliferation, invasion, and migration [5].
No KO/CKO mouse models were directly mentioned in the provided references. However, from the studies on different diseases, we can infer that Nrg2 has diverse functions. In solid tumors, its fusion may drive oncogenesis; in prostate, it is involved in regeneration; in gliomas, it affects cell migration; and in breast cancer, it acts as a tumor suppressor. Although not demonstrated through KO/CKO mouse models in these references, these findings suggest the importance of further in-vivo studies, potentially using gene knockout models, to fully understand the role of Nrg2 in these biological processes and disease conditions.
In conclusion, Nrg2 is involved in multiple biological processes and disease conditions. Its functions range from promoting prostate regeneration to playing a role in the development and progression of various cancers, such as solid tumors, gliomas, and breast cancer. While the exact mechanisms are yet to be fully elucidated, especially through gene-knockout-based in-vivo studies, the current findings highlight its significance in understanding disease mechanisms and potentially developing targeted therapies.
References:
1. Nagasaka, Misako, Ou, Sai-Hong Ignatius. 2022. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. In Trends in cancer, 8, 242-258. doi:10.1016/j.trecan.2021.11.003. https://pubmed.ncbi.nlm.nih.gov/34996744/
2. Karthaus, Wouter R, Hofree, Matan, Choi, Danielle, Regev, Aviv, Sawyers, Charles L. . Regenerative potential of prostate luminal cells revealed by single-cell analysis. In Science (New York, N.Y.), 368, 497-505. doi:10.1126/science.aay0267. https://pubmed.ncbi.nlm.nih.gov/32355025/
3. Zhao, Wei-Jiang, Yi, San-Jun, Ou, Guan-Yong, Qiao, Xin-Yu. . Neuregulin 2 (NRG2) is expressed in gliomas and promotes migration of human glioma cells. In Folia neuropathologica, 59, 189-197. doi:10.5114/fn.2021.106460. https://pubmed.ncbi.nlm.nih.gov/34284546/
4. Trombetta, Domenico, Sparaneo, Angelo, Fabrizio, Federico Pio, Rossi, Antonio, Muscarella, Lucia Anna. 2021. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. In Expert opinion on therapeutic targets, 25, 865-875. doi:10.1080/14728222.2021.1999927. https://pubmed.ncbi.nlm.nih.gov/34706602/
5. Zhou, Ruijie, Dai, Jinjin, Zhou, Runlong, Yao, Di, Xu, Yao. 2024. Prognostic biomarker NRG2 correlates with autophagy and epithelial‑mesenchymal transition in breast cancer. In Oncology letters, 27, 277. doi:10.3892/ol.2024.14410. https://pubmed.ncbi.nlm.nih.gov/38699660/
6. Xu, Chunwei, Wang, Qian, Wang, Dong, Chen, Jing, Song, Zhengbo. 2024. Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors. In Global medical genetics, 11, 86-99. doi:10.1055/s-0044-1781457. https://pubmed.ncbi.nlm.nih.gov/38414979/
7. Czarnek, Maria, Bereta, Joanna. 2019. Proteolytic Processing of Neuregulin 2. In Molecular neurobiology, 57, 1799-1813. doi:10.1007/s12035-019-01846-9. https://pubmed.ncbi.nlm.nih.gov/31838721/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。